Evaluation of Clinical Response Using Single Agent Prednisolone for the Treatment of Canine Mast Cell Tumor: A Retrospective Study
Date Issued
2011
Date
2011
Author(s)
Tsao, Chun-Chao
Abstract
Mast cell tumors (MCTs) are the most common cutaneous tumor in dogs, comprising 16-21 % of all cutaneous tumors. The treatment options of canine MCTs nowadays are mostly managed by combination protocols. Among internal medicine management, one commonly used drug is prednisolone, which is proven to have efficacy in treating canine MCTs in previous studies. However, no report to date has completely evaluated the response of single agent regimen of prednisolone as the choice of canine MCTs treatment. The aim of this study is to evaluate clinical response using single agent prednisolone in the treatment of canine MCTs, including overall response rate (ORR), median response duration (MRD), disease free interval (DFI), and time to treatment failure (TFF). 67 cases were collected into this study through 2001 to 2010.ORR was 65%. Of these cases (38/67), 25 was partial remission, 11 was stable disease, and other 2 were complete remission and progressive disease, respectively. It was higher than most previous clinical trials including single and combinational agent therapies. 38 cases had measurable disease, and the MRD was 39.5 days. Median TTF was 66 days. 27 cases (42%) had no measurable disease, and the median DFI was 54 days. Median TTF was 67 days. The MRD and median DFI were obvious shorter than others clinical reports. In general, the side effects of prednisolone treatment were well tolerated in present study. Regional lymph node status (p=0.04) and treatment response (p=0.013) were significant factors of response duration (RD). And breed of dogs was significant predictor of DFI (p=0.043). There were no significant factors for TTF of group that dogs with gross obvious tumors. But breed of dogs (p=0.031) and treatment response (p=0.013) were significant predictors of TTF of group that dogs without gross obvious tumors. There was no statistical difference of RD and TTF neither between the group that dogs treat with single agent prednisolone and the group that dogs treat with combinational prednisolone and cyclophosphamide or the group that dogs treat with single agent prednisolone and the group that dogs treat with combinational prednisolone and vinblastine. Owing to the characteristic of high response rate and short-term response duration and disease free interval in single agent prednisolone protocol, we conclude that it was an effective single regimen used in treat canine MCTs before wide-margin surgery in order to obtain adequate surgical margin. However, if patients of canine MCTs were treated with chemotherapy alone for long time, it had better choose multiple combinational protocols rather than single regimen of prednisolone.
Subjects
Dog
Canine mast cell tumors
Retrospective study
Chemotherapy
Type
thesis
File(s)![Thumbnail Image]()
Loading...
Name
ntu-100-R97643012-1.pdf
Size
23.32 KB
Format
Adobe PDF
Checksum
(MD5):1c9de588b78e67d63e1a85194ea4d307